跳至主要内容
临床试验/NL-OMON56597
NL-OMON56597尚未招募不适用

A prospective, randomized study comparing chemotherapy versus chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer with low cTML and oncogenic driver,STK11 or KEAP1 mutation and a PD-L1 TPS<50%. - OMIT IO

eids Universitair Medisch Centrum0 个研究点目标入组 162 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
162

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Age >18 years 2. Advanced, metastatic non-small cell lung cancer UICC stage
  • IV 3. ECOG PS 0-2 4. PDL-1 TPS <50% (Dako 22C3) 5. Low cTML (<300 nonsynonymous
  • mutations) and either actionable mutation, inactivating STK11 or KEAP1
  • mutations as detected by NGS using OCA+ or TSO500 gene panel. 6. No prior
  • systemic therapy except for patients with activating mutations. 7. Fit for
  • treatment with chemo-immunotherapy deemed by the treating physician. 8.
  • Measurable disease (RECIST 1.1). 9. In case of activating mutation,
  • pretreatment with appropriate (i.e. guideline recommended) targeted therapy is
  • required with demonstrated disease progression.

排除标准

  • 1. Symptomatic CNS metastasis requiring immediate radiotherapy or neurosurgical
  • intervention.
  • 2. Any contra-indication (as per label) for treatment with immune checkpoint
  • inhibitors.

研究者

相似试验